-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of increasing population aging, the arrival of the three-child era, and consumption upgrades, the pharmaceutical track is recognized as an industry with a broader and more certain future development space
.
Affected by this, many investors are also focusing more and more on the pharmaceutical field and continue to increase their layout
.
Among them, Hillhouse's preference and layout of biomedicine are very obvious in the pharmaceutical market
.
According to agency statistics, Hillhouse has invested in at least 15 A-share biomedical companies, and almost all of them are leaders on the track
.
It is understood that these companies include: Hengrui Pharmaceuticals, WuXi AppTec, Aier Ophthalmology, Tigermed, Hualan Biological, Ganli Pharmaceutical, Kailai Ying, Jinyu Medical, Jianfan Biological, BGI, Dean Diagnostics, Jun real biology
.
According to industry analysts, it is obvious from the annual reports of these companies that medical biology has become the main battlefield
.
Specifically, the Aier Ophthalmology Interim Report showed that Hillhouse Capital's holding ratio in the second quarter only dropped by 0.
02%, and it is still its sixth largest shareholder
.
After quitting Hengrui Pharmaceutical’s top ten shareholders in 2017, Hillhouse re-purchased more than 40 million shares of Hengrui Pharmaceuticals in the second quarter of this year, becoming one of its largest shareholders, holding a market value of approximately 2.
7 billion
.
Also in the list of the top ten outstanding shares of Jianfan Bio, Hillhouse Capital’s offshore UBS account UBSAG (UBS) is also among them.
After four consecutive quarters of reductions, the number of shares held has dropped from 13.
22 million shares to 880 Million shares
.
In addition, on February 1, 2021, Hillhouse Capital also invested 503 million yuan to purchase 3.
46 million shares of Huada Gene at a price of 145.
00 yuan per share, with a fixed increase lock-up period of 6 months
.
In addition to the above investment, according to incomplete statistics, Hillhouse has so far invested in more than 200 companies in the fields of biomedicine, medical equipment, medical services, pharmaceutical outsourcing, and pharmaceutical retail, among which more than 100 Chinese companies have a total investment The amount is around 200 billion yuan
.
It’s worth mentioning that Hillhouse has added benefits to the blue eyes of the biomedical track, no matter in the secondary market or in other markets.
.
From the perspective of project preferences, Hillhouse's biomedicine layout can be classified into two main categories: one is monoclonal antibody biologics; the other is tumor immunotherapy
.
In the field of monoclonal antibody biomedicine, Hillhouse's first promising project in the field of biomedicine is BeiGene for the development of PD-1
.
At the same time, Hillhouse has also invested in a number of other biopharmaceutical companies with PD-1 as the main product, including Junshi Bio, Xinda Bio, Jiahe Bio, CStone Pharmaceuticals and other companies that produce PD-1 and PD-L1 monoclonal antibodies.
Business
.
It should be noted that on January 18 this year, the founder of Hillhouse made it clear at the Asian Financial Forum: In the post-epidemic era, Hillhouse Capital’s major investment will still be in China's medical industry
.
In this regard, the industry believes that the domestic pharmaceutical and medical industries are in a stage of vigorous development.
In addition to the hills, more and more capital will also increase the layout of domestic pharmaceutical companies in the future to promote China's pharmaceutical and medical industries on the road of high-quality development.
.
In addition, the industry has proposed that a large number of pharmaceutical companies that have anticipated their performance in the first half of this year are mainly concentrated in sectors such as medical services, health consumption and technological innovation, as well as ophthalmology, traditional Chinese medicine, epidemic-related, CXO, equipment and other fields.
It can be seen that the long-term growth certainty of the leading companies on the above tracks will be higher, and they are expected to perform more strongly in the follow-up market
.
Therefore, investors can focus on the development trend of certain sub-sectors and companies, such as biological hot scene, Huaxi Sheng was Columbine medicine and so on
.
.
Affected by this, many investors are also focusing more and more on the pharmaceutical field and continue to increase their layout
.
Among them, Hillhouse's preference and layout of biomedicine are very obvious in the pharmaceutical market
.
According to agency statistics, Hillhouse has invested in at least 15 A-share biomedical companies, and almost all of them are leaders on the track
.
It is understood that these companies include: Hengrui Pharmaceuticals, WuXi AppTec, Aier Ophthalmology, Tigermed, Hualan Biological, Ganli Pharmaceutical, Kailai Ying, Jinyu Medical, Jianfan Biological, BGI, Dean Diagnostics, Jun real biology
.
According to industry analysts, it is obvious from the annual reports of these companies that medical biology has become the main battlefield
.
Specifically, the Aier Ophthalmology Interim Report showed that Hillhouse Capital's holding ratio in the second quarter only dropped by 0.
02%, and it is still its sixth largest shareholder
.
After quitting Hengrui Pharmaceutical’s top ten shareholders in 2017, Hillhouse re-purchased more than 40 million shares of Hengrui Pharmaceuticals in the second quarter of this year, becoming one of its largest shareholders, holding a market value of approximately 2.
7 billion
.
Also in the list of the top ten outstanding shares of Jianfan Bio, Hillhouse Capital’s offshore UBS account UBSAG (UBS) is also among them.
After four consecutive quarters of reductions, the number of shares held has dropped from 13.
22 million shares to 880 Million shares
.
In addition, on February 1, 2021, Hillhouse Capital also invested 503 million yuan to purchase 3.
46 million shares of Huada Gene at a price of 145.
00 yuan per share, with a fixed increase lock-up period of 6 months
.
In addition to the above investment, according to incomplete statistics, Hillhouse has so far invested in more than 200 companies in the fields of biomedicine, medical equipment, medical services, pharmaceutical outsourcing, and pharmaceutical retail, among which more than 100 Chinese companies have a total investment The amount is around 200 billion yuan
.
It’s worth mentioning that Hillhouse has added benefits to the blue eyes of the biomedical track, no matter in the secondary market or in other markets.
.
From the perspective of project preferences, Hillhouse's biomedicine layout can be classified into two main categories: one is monoclonal antibody biologics; the other is tumor immunotherapy
.
In the field of monoclonal antibody biomedicine, Hillhouse's first promising project in the field of biomedicine is BeiGene for the development of PD-1
.
At the same time, Hillhouse has also invested in a number of other biopharmaceutical companies with PD-1 as the main product, including Junshi Bio, Xinda Bio, Jiahe Bio, CStone Pharmaceuticals and other companies that produce PD-1 and PD-L1 monoclonal antibodies.
Business
.
It should be noted that on January 18 this year, the founder of Hillhouse made it clear at the Asian Financial Forum: In the post-epidemic era, Hillhouse Capital’s major investment will still be in China's medical industry
.
In this regard, the industry believes that the domestic pharmaceutical and medical industries are in a stage of vigorous development.
In addition to the hills, more and more capital will also increase the layout of domestic pharmaceutical companies in the future to promote China's pharmaceutical and medical industries on the road of high-quality development.
.
In addition, the industry has proposed that a large number of pharmaceutical companies that have anticipated their performance in the first half of this year are mainly concentrated in sectors such as medical services, health consumption and technological innovation, as well as ophthalmology, traditional Chinese medicine, epidemic-related, CXO, equipment and other fields.
It can be seen that the long-term growth certainty of the leading companies on the above tracks will be higher, and they are expected to perform more strongly in the follow-up market
.
Therefore, investors can focus on the development trend of certain sub-sectors and companies, such as biological hot scene, Huaxi Sheng was Columbine medicine and so on
.
